Bromocriptine in the Treatment of Acromegaly
Bromocriptine is a dopamine agonist which suppresses prolactin secretion in healthy people and in patients with prolactin secreting tumours. It increases growth hormone secretion in some normal subjects but paradoxically lowers growth hormone secretion in up to 70% of patients with acromegaly.
Reports on the efficacy of bromocriptine therapy in acromegaly vary widely. Growth hormone levels are reduced in the majority of patients but are rarely completely suppressed. Greater remission of the soft tissue features of acromegaly may occur in some patients than would be expected from changes in growth hormone levels as determined by immunoassay.
The major advantage of bromocriptine therapy in acromegaly is its lack of effect on pituitary function, other than growth hormone and prolactin secretion, and avoidance of the complications of surgical or radiation treatment. Its major disadvantages are that the majority of patients only show a partial response, and the degree of compliance required with long term therapy. It is a useful adjunct to surgical and radiation treatment. In the few large studies of bromocriptine treatment used alone the results obtained over a limited period compare favourably with those obtained by radiotherapy.
KeywordsGrowth Hormone Prolactin Acromegaly Bromocriptine Dopamine Agonist
Unable to display preview. Download preview PDF.
- Besser, G.M.; Thorner, M.O. and Wass, J.A.H.: Bromocriptine treatment of acromegaly; in Proceedings of a Symposium of Royal College of Physicians, London (Sandoz, 1976)Google Scholar
- Clark, B.J.; Fluckiger, E.; Loew, D.M. and Vigouret, J.M.: How does bromocriptine work? Triangle 17: 21 (1978)Google Scholar
- Faglis, G.; Paracchi, A.; Beck-Peccoz, P. and Ferrari, C.: An explanatory hypothesis for plasia GH response to non-specific releasing hormones and pr ‘paradoxical’ GH inhibition after dopaminergic drugs in acromegaly. Acta Endocrinologica Suppl. 199: 323 (1975)Google Scholar
- Fraser, R.: The assessment of the endocrine effects and the effectiveness of ablative pituitary treatment by 90Y and 198Au implantation; in Kohler and Ross (Eds) Diagnosis and Treatment of Pituitary Tumours, p.35 (Excerpta Medica, Amsterdam 1973)Google Scholar
- Gordon, P. and Roth, J.: The treatment of acromegaly by conventional pituitary irradiation; in Kohler and Ross (Eds) Diagnosis and Treatment of Pituitary Tumours p.230 (Excerpta Medica, Amsterdam 1973)Google Scholar
- Kjellberg, R.N. and Kliman, B.: A system for therapy of pituitary tumours; in Kohler and Ross (Eds) Diagnosis and Treatment of Pituitary Tumours p.234 (Excerpta Medica, Amsterdam 1973)Google Scholar
- Liuzzi, A.; Chiodini, P.G.; Botalla, L.; Silvestrini, F. and Muller, E.E.: Growth hormone (GH) — releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogenecity in the two responses. Journal of Clinical Endocrinology and Metabolism 39: 871 (1974)bPubMedCrossRefGoogle Scholar
- Liuzzi, A.; Verde, G. and Chiodini, P.G.: Dopaminergic control of growth hormone secretion in acromegaly. Triangle 17: 41 (1978)Google Scholar
- Vaidya, R.; Alookar, S. and Sheth, A.: Therapeutic regression of putative pituitary hyperplasia and/or microadenoma with CB-154. Fertility and Sterility 28: 363 (1977)Google Scholar